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Abbreviations 
AIH autoimmune hepatitis 
ALD alcoholic liver disease 
APRI AST platelet ratio index 
AUROC area under the receiver operating curve 
BMI body mass index 
CI  confidence interval 
CSPH clinically significant portal hypertension 
CT computed tomography 
HBV hepatitis B virus 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HR hazard ratio 
HVPG Hepatic venous pressure gradient 
HU Houndsfield unit 
INR international normalized ratio 
IMATI intramuscular adipose tissue index 
IQR interquartile range 
L3 third lumbar vertebra 
LSPS liver stiffness*spleen size over platelets risk score 
MELD Model for End-Stage Liver Disease 
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MELD-Na MELD –Sodium model 
MRI magnetic resonance imaging 
NAFLD Nonalcoholic fatty liver disease 
NASH nonalcoholic steatohepatitis 
PBC primary biliary cirrhosis 
PMI psoas muscle index 
PSC primary sclerosing cholangitis 
SATI subcutaneous adipose tissue index 
SMI skeletal muscle index 
TATI total adipose tissue index 
TIPS transjugular intrahepatic portosystemic shunt 
VATI visceral adipose tissue index 
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Abstract 
Background & Aims. In cirrhosis, hepatic venous pressure gradient (HVPG) and 
imaging body composition assessment can influence prognosis. We assessed 
whether adipose and skeletal muscle tissue reflect the severity of portal hypertension 
(PH), and whether they improve non-invasive prediction of decompensation and 
death.   
 
Methods: We included 84 cirrhosis patients with HVPG and computed tomography 
(CT) within 12 weeks of HVPG at a single centre. L3 vertebra CT images were used 
for body composition indexes (cm2/m2): total adipose tissue index (TATI), visceral 
adipose tissue index (VATI), subcutaneous adipose tissue index (SATI), 
intramuscular adipose tissue index (IMATI), skeletal muscle index (SMI) and psoas 
muscle index (PMI). Correlations were calculated between indexes, HVPG and 
standard non-invasive tests for PH. 12-month decompensation and death predictors 
were determined. 
 
Results: Male 61%; BMI 28±5 kg/m2; alcoholic liver disease in 51%, non-alcoholic 
steatohepatitis in 24%; HVPG 14±6 mmHg; 45% compensated. Median follow-up 
was 11 (4-17) months. HVPG correlated with SATI (r=-0.282,p=0.01), TATI (r=-
0.220,p=0.045) and SATI/VATI index (r =-0.240,p=0.03). In compensated patients, 
lower VATI (HR 0.94 (0.90-0.99), p=0.01) was associated with 12-month 
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decompensation. Combining TATI and liver stiffnessxspleen size over-platelet count 
risk score (LSPS) added discriminative capacity for 12-month decompensation 
(AUROC 0.91 vs. 0.87). IMATI was independently associated with mortality in 
decompensated patients. MELD-Na combined with IMATI discriminated excellently 
for mortality (AUROC 0.94; p<0.001). 
 
Conclusions: HVPG inversely correlates with imaging markers of adipose tissue, 
while markers of sarcopenia were unrelated to PH. In compensated patients, TATI 
improves non-invasive prediction of decompensation. In decompensated patients, 
IMATI independently predicted mortality.  
 
Keywords: advanced chronic liver disease; body composition; portal hypertension; 
computed tomography;  
 
Lay summary 
We assessed whether fat and muscle tissue reflect the severity of portal vein 
pressure and whether it improves non-invasive prediction of decompensation and 
death in patients with liver cirrhosis. Portal pressure inversely correlates with imaging 
markers of fat tissue, while markers of muscle wasting were unrelated to portal 
pressure. In compensated patients, total fat index improves non-invasive prediction 
of decompensation. In decompensated patients, fatty infiltration of muscle 
independently predicted mortality. Although further validation of these findings is 
needed, our findings suggest that on CT-based body composition assessment 
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muscle and fat compartments should be taken into account to allow an appropriate 
risk stratification for decompensation and death in cirrhosis. 
 
Introduction 
Risk stratification in patients with cirrhosis is paramount to achieve a personalized, 
pathophysiology stage-oriented approach. 1 Well-established prognostic markers in 
cirrhosis include liver function (albumin, bilirubin, International Normalized Ratio, 
Model for End-stage Liver Disease score), presence of complications (ascites, 
gastro-oesophageal varices) and hepatic venous pressure gradient (HVPG), the 
accepted equivalent of portal pressure. 2  In compensated patients, HVPG is the 
single best prognostic factor, and it has been associated with the risk of developing 
varices, first clinical decompensation and hepatocellular carcinoma.2,3 In 
decompensated patients, HVPG predicts recurrent variceal bleeding and survival. 2,4 
Over the last years, nutritional status and body composition have emerged as 
determinants of outcome in cirrhosis and are gaining increasing attention.5 
Importantly, these can be explored non-invasively in patients with cirrhosis by 
measuring adipose tissue and skeletal muscle components on cross-sectional 
imaging, such as computed tomography (CT).6, 7–11 Sarcopenia – a reduction in 
skeletal muscle mass – has been proven associated with worse prognosis in patients 
with decompensated cirrhosis.12–15 Recently fat tissue depletion – adipopenia – has 
been additionally associated with higher mortality in women with cirrhosis.15 
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Inflammation underlying to changes in body composition in patients with cirrhosis 
could be potentially due in part to portal hypertension, and vice-versa,  the 
inflammatory crosstalk between fat, muscle and the liver occurring in cirrhosis could 
lead to an increase in portal pressure.16 Until date, no study has specifically 
evaluated the relationship between HVPG and imaging markers of adipose tissue 
and skeletal muscle in patients with cirrhosis, and whether body composition on 
imaging and portal pressure should be considered independent prognostic markers. 
Our study aimed at addressing these questions. 
 
Methods 
Study Population and endpoints 
All consecutive patients (≥ 18 years) who underwent measurement of HVPG and 
TJLB between January 2015 and March 2018 were screened for the inclusion in this 
study. 
 
We included those fulfilling all the following criteria: a) histologically proven cirrhosis, 
b) abdominal computed tomography (CT) within (before or after) 12 weeks of HVPG 
measurement, and c) clinical follow-up at our centre. Exclusion criteria were: 
absence of cirrhosis on histology, malignancy (including HCC), or end-stage heart, 
kidney or lung disease (see flowchart Supplementary Figure 1).  
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HVPG and TJLB were indicated to further characterize liver disease. CT scan was 
performed for HCC screening in patients unsuitable for ultrasound assessment, in 
the context of further characterization of patients on first diagnosis or 
decompensation, or as a routine workup for inclusion for the liver transplantation 
waiting list. Baseline clinical and laboratory data were determined on the day of 
HVPG measurement. Patients were considered “compensated” on inclusion if no 
episode of clinical decompensation (ascites, variceal bleeding, hepatic 
encephalopathy) was present in the past or on inclusion. 
 
The selection of patients was performed by two hepatologists, blinded to CT findings. 
The evaluation of body composition markers on CT images was performed at the 
end of the patient selection by an expert radiologist blinded to the patients’ clinical 
data, including HVPG value.  
 
Patients were followed-up until end of September 2018. First or subsequent 
episodes of clinical decompensation (oesophago-gastric variceal bleeding, ascites, 
hepatic encephalopathy, spontaneous bacterial peritonitis or hepatorenal syndrome), 
liver-related death and transplantation were collected. Portal vein thrombosis, HCC 
or other cancer onset in the absence of clinical decompensation (n=3) were not 
considered as “decompensation” of cirrhosis. Patients lost to follow-up were 
censored for at the date of the last visit. 
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All patients provided informed written consent to the HVPG procedure and signed 
the general consent form for the use of their health-related data. The Canton of Bern 
Research Ethics Committee (KEK 2018-00487) approved the study. 
 
Clinical Data collection 
Baseline patients’ characteristics such as demographical data (age, gender), 
aetiology, medication, history of liver disease, Child-Pugh and MELD scores, 
laboratory, ultrasonographic and endoscopic findings were collected from the 
hospital’s electronic database.  Liver stiffness (LS) values were obtained using 
transient elastography. Liver stiffness x spleen diameter to platelet ratio (LSPS) was 
calculated as follows: LS value * spleen diameter/platelet count.17 
 
Hemodynamic study and transjugular liver biopsy  
On fasting conditions and under local anaesthesia, a 9F venous catheter introducer 
(Radiofocus Introducer II, Terumo, Japan) was placed in the right jugular vein (in one 
case: left jugular vein) under ultrasonographic guidance (SonoSite Inc, Bothell, WA, 
USA) using the Seldinger technique. Under pulsed fluoroscopy control, a 5 or 6F 
multipurpose catheter (Tempo 5 or 6 MPA1, Cordis, Ireland) was advanced into a 
main hepatic vein of the right lobe with the help of a hydrophilic guidewire 
(Radiofocus Guidewire M Stiff type angled, Terumo, Japan). A 6F balloon‐tipped 
catheter (Cook Medical, Bloomington, IN, USA) was then used to measure hepatic 
venous pressures (Pressure transducer: Xtrans, CODAN Pvb Critical Care GmbH, 
Forstinning, Germany). Free hepatic venous pressure was measured by maintaining 
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the tip of the catheter free in the hepatic vein at 2-4 cm from its opening into the vena 
cava inferior. Wedged hepatic venous pressure was measured by occluding the 
hepatic vein by inflating the balloon at the tip of the catheter. All measurements were 
taken as triplicates and permanent tracings were obtained with a multichannel 
recorder (Sensis Dialog, Siemens Healthcare GmbH, Erlangen, Germany). Portal 
hypertension was classified as subclinical if HVPG was 6-9 mm Hg and clinically 
significant if ≥10 mm Hg. Very severe portal hypertension was diagnosed if HVPG ≥ 
16 mm Hg, due to its associated increased risk of mortality.2 
 
After the measurements, 2 mL ICM were injected to confirm that the anatomy and 
size of the hepatic vein was appropriate to perform liver biopsy. Transjugular liver 
biopsy was performed as previously described.18 
 
CT evaluation 
Imaging biomarkers of body composition included skeletal muscle (SM), and adipose 
tissues (visceral-VAT; intramuscular-IMAT and subcutaneous-SAT). These were 
measured by analysis of CT images at the level of the third lumbar (L3) vertebra by 
using a semi-automatic software (SliceOmatic™ V 5.0, Tomovision, Montreal, 
Quebec, Canada). The cross-sectional area of skeletal muscles and subcutaneous 
or visceral adipose tissue were measured in units of squared centimetres. Skeletal 
muscles assessed included the psoas, erector spinae, quadratus lumborum, 
transversus abdominis, external and internal obliques, and rectus abdominis 
muscles. The different tissue types were selected by using tissue-specific Hounsfield 
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unit (HU) thresholds. The CT HU thresholds were -29 to 150 for skeletal muscles7 -
190 to -30 for subcutaneous adipose tissue, and -150 to -50 for visceral adipose 
tissue. Using these HUs, adipose tissue within the abdominal wall was quantified as 
visceral adipose tissue. The subcutaneous adipose tissue cross-sectional area was 
estimated as the area between the skin line and outer abdominal wall.8–11 Values 
were normalized for stature in squared meters and results are provided as indexes 
(I) as follows: skeletal muscle index (SMI), psoas muscle index (PMI), total adipose 
tissue index (TATI), subcutaneous adipose tissue index (SATI), and visceral adipose 
tissue index (VATI) in units of centimetres squared/meters squared. Intramuscular 
adipose tissue index (IMATI) was similarly.19 Sarcopenia was diagnosed using cut-
offs previously published in Western population of liver transplant candidates of an 
L3 muscle area normalized to height (SMI) of 50 cm2/m2 for men and 39 cm2/m2 for 
women).20 Subcutaneous adipopenia (SATI < 60m2/cm2) was previously associated 
with mortality in patients with cirrhosis.15 SATI over VATI index reflected the 
relationship between visceral and subcutaneous adipose tissue. 
 
Statistical analysis 
Continuous variables are presented as both as mean and standard deviation (SD) 
and in median and interquartile range. T-test for independent sample was used to 
compare differences in means.  For categorical variables, descriptive statistics are 
presented as frequency and percentages and the comparison between study groups 
was conducted using Pearson chi-squared test. Correlations between body 
composition markers and HVPG were determined by either Pearson’s correlation 
coefficient (r) or Spearman’s rho coefficient analysis. When assessing mortality and 
decompensation, patients were censored at the time of the last visit. Significant 
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predictors of mortality and decompensation were determined using univariate and 
multivariate Cox proportional hazard models and the results were reported as hazard 
ratios (HR) and 95% confidence intervals (CI). To avoid overfitting on multivariate 
analysis, 1 variable per 5 events was entered into the model.21 For the model 
predicting mortality, MELD-Na was chosen because it incorporated the most 
significant parameters in univariate analysis, thereby avoiding collinearity. Areas 
under the operating receiver curve (AUROC) were calculated to determine the 
discriminative ability of HVPG and non-invasive tests for decompensation and death. 
Data were analysed using SPSS (version 25; IBM, Armonk, NY). A sub-analysis for 
gender was conducted. A P value < 0.05 was considered statistically significant. 
 
Results 
The general baseline characteristics of the 84 patients fulfilling the inclusion criteria 
are shown in Table 1. Fifty-one patients were male (61%) with a mean age of 57±11 
years. In 75% of the cases, the patients had either alcohol-related or metabolic 
syndrome-associated cirrhosis, or both. In fact, the majority of patients were 
overweight with a mean BMI of 28±5 Kg/m2. The mean Child-Pugh and MELD 
scores were similar in both genders. Thirty-eight patients (45%) were fully 
compensated at the time of HVPG measurement. Among the 46 (55%) 
decompensated patients 32 had ascites, 8 had hepatic encephalopathy and 6 had a 
recent episode of variceal bleeding. 13% had decompensated within a month prior to 
the HVPG measurement. The overall mean HVPG was 14.0±6 mm Hg, similar for 
male compared to female patients with 14.5±6 vs. 13.3±6 mm Hg (p=0.39). Median 
follow-up time (IQR) was 11 (4-18) months.  
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Seven out of the 38 patients (18%) with compensated cirrhosis presented a first 
episode of clinical decompensation in the follow-up. Sixteen patients (19%) died 
(death in 24% men vs. 12% women; p=0.26). The causes of death were as follows: 
liver failure (8), sepsis (4), HCC (2), cholangiocarcinoma (1) and 1 of unclear cause. 
 
Body composition analysis 
The mean BMI was for males: 29±6 kg/m2 and females: 28±5 kg/m2 (Supplementary 
Table 1).  Among males and females the prevalence of sarcopenia, using the 
established cut-offs were: 69% and 45%, respectively (p=0.04). VATI was higher for 
males 71±34 vs. 48±26 cm2/m2 (p=0.001).  
 
Notably, VATI was significantly higher in alcoholic liver disease (ALD) and non-
alcoholic fatty liver disease (NAFLD) versus other aetiologies (p=0.048). Patients 
with previous or ongoing decompensation and MELD score ≥16 had significantly 
lower SATIs compared to compensated patients (p=0.04 and p=0.048, respectively) 
(Figure 1).   
 
Correlation of imaging body composition markers and HVPG  
No significant correlation was found between HVPG and SMI or PMI, nor with 
sarcopenia (Table 2). On the other hand, HVPG showed significant inverse 
correlations with adipose tissue indexes: SATI (r= -0.282, p=0.01), TATI (r= -0.220, 
p=0.045) and SATI-over-VATI index (r =-0.240, p=0.03).   
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As shown in Table 3, SATI was lower in patients with higher HVPG: 91±47 cm2/m2 in 
patients with subclinical portal hypertension, 72±40 cm2/m2 in patients with HVPG 
10-12 mmHg (p=0.028 vs. subclinical) and 65±33 cm2/m2 (p=0.028 vs. subclinical) in 
patients with HVPG≥16 mmHg (very severe PH). 
 
Correlation of HVPG with imaging body composition markers, and other non-
invasive markers of portal hypertension  
In the current study population, LSPS correlated well with the HVPG (r=0.65, 
p<0.001) (Suppl. Table 2). The strength of the correlation was particularly strong in 
women (r=0.84, p<0.001) and in patients with aetiologies other than ALD or NAFLD 
(r=0.82, p<0.001).  
 
Patients with compensated cirrhosis: Factors associated with the risk of first 
decompensation at 12 months  
Table 4 shows the univariate analysis of factors associated with first clinical 
decompensation at 12 months. As shown, LS, platelet count, their combination into 
the LSPS, HVPG and CT fat compartment areas TATI and VATI and their ratio were 
associated with this outcome. Given the low number of events, Cox multivariate 
regression analysis was limited to 2 variables at a time. LSPS (which included 2 of 
the significant variables in univariate analysis: LS and platelet count) was tested in a 
model with each: TATI, VATI and SATI/VATI. Among the three, TATI was the 
strongest in the model combining LSPS. Therefore, LSPS combined with TATI 
constitutes our final model. 
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As for the discriminative ability of non-invasive tests for predicting clinical 
decompensation, liver stiffness had an AUROC of 0.77 (95%CI 0.57-0.98, p=0.04), 
AST to platelet ratio index (APRI) of 0.84 (95%CI 0.66-0.99 p=0.01), LSPS of 0.87 
(95%CI 0.74-0.99, p=0.004) and LSPS-TATI of 0.91 (95%CI 0.80-0.99, p=0.002) 
(Figure 2). 
 
Factors associated with 12-month mortality  
The mortality rate in our population was relatively low (n=16 events at 12 months; 
19%) and occurred exclusively in decompensated patients. In univariate analysis the 
significant variables associated with death included: age, bilirubin, MELD, Na, Child-
Pugh, TATI, VATI and IMATI. Cox regression analysis was limited to 3 variables at a 
time, given the low number of events. As MELD, Child-Pugh and bilirubin were 
collinear, the strongest one, MELD, was selected and MELD-Na was calculated, as 
Na was a significant variable. The variables VATI and IMATI were collinear with TATI 
and so the strongest, IMATI (HR 1.14, 95% CI, 1.06-1.23, P=0.001) for both males 
and females, was chosen.  Therefore, MELD-Na combined with IMATI constitutes 
our final model. As compared to standard scores predicting mortality, the 
combination of MELD-Na-IMATI was superior to Child-Pugh, MELD 0.85 (95%CI 
0.72-0.97, p=0.001) and MELD-Na scores (Figure 2). 
 
Discussion 
This is the first study analysing the relationship between portal pressure and both fat 
and muscle body composition markers in a Western cohort of well-characterized 
patients with compensated and decompensated cirrhosis. A previous study 
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conducted in Asia showed that psoas muscle area was an independent predictor for 
long-term mortality in cirrhotic patients with ascites, but showed no significant 
correlation between HVPG and psoas muscle thickness index.22 Recently, another 
Asian group studied the impact of sarcopenia on mortality in compensated and early-
decompensated patients with cirrhosis and HVPG measurements, in a distinct 
population from ours, showing no correlation between HVPG and sarcopenia.23  
 
In the present study, in addition to muscle, we evaluated fat compartments, and our 
patients were histologically diagnosed with cirrhosis. In our cohort, we confirm no 
association between muscle mass and HVPG; however, we could demonstrate that 
HVPG significantly and inversely correlated with SATI particularly in females, 
decompensated patients and those with ALD or NASH cirrhosis. In patients with a 
very high HVPG value (≥16 mmHg), which indicates a higher risk of death2, SATI – 
but not VATI – was much lower than in patients with earlier stages of portal 
hypertension. The depletion of the TATI also significantly correlated with HVPG, and 
was particularly important among patients with sarcopenia.  
 
These findings highlight that, while muscle depletion shows no relationship with 
portal pressure itself, fat loss and portal hypertension are related. Until very recently, 
attention has been focused on sarcopenia; however, the importance of VAT 
abundance and SAT depletion has become a matter of interest. 24,25 Subcutaneous 
adipose tissue is the metabolically more favourable fat compartment26, and, in most 
patients, the most abundant within total adipose tissue. From a clinical point of view, 
it has been observed that a healthy amount of SAT may imply a survival benefit.26 
Specifically, among women with cirrhosis, it was hypothesized that higher SAT 
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
allowed these patients to endure weight losses and subsequent longer overall 
survival15; similar findings have been shown in patients with cancer.27  In animal 
models, the removal of subcutaneous fat is associated with increase in visceral fat 
mass, insulin resistance, circulating insulin, and TNF-α.28 These changes imply a 
pro-inflammatory state that could negatively influence the progression of cirrhosis 
and portal hypertension. Recent evidence in animal models of cirrhosis29,30 and in 
patients with cirrhosis and obesity undergoing an intensive life-style intervention 
support that improvement in the adipokine profile could improve portal 
hypertension.31 Whether achieving an increase in SAT could represent a strategy to 
modulate favourably portal pressure remains a field for future research. 
 
Besides confirming that a clear sex difference exists, as for the prognostic meaning 
of fat depletion, our findings suggest that the relationship between body composition 
markers and severity of portal hypertension are aetiology-dependent. In our cohort, 
there was a clear predominance of patients with ALD and NAFLD, accounting for 
75% of patients, which differentiates our population from most previous studies, 
largely including patients with viral hepatitis and patients with HCC. Additionally, the 
mean visceral adipose tissue compartment, VATI, was higher than in previously 
reported series (mean VATI 62±33 cm2/m2 in our cohort vs. < 40 cm2/m2 in previous 
cohorts).15 
 
Regarding prognosis, the inclusion of compensated patients provides an insight into 
the prevalence and disparities in body composition among different stages of 
cirrhosis, which are key to guide management.1 Unsurprisingly, sarcopenia and 
significant adipopenia, and particularly SAT depletion, were more common in 
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decompensated patients. However, about 20% of fully compensated patients 
showed features of subcutaneous adipopenia, highlighting a group of increased risk 
of progression that could be likely susceptible to early intervention.  
 
Furthermore, we addressed the relationship between body composition markers and 
first clinical decompensation, which is the most important endpoint in compensated 
patients.1 Regarding this, we found that in addition to expected factors, such as 
HVPG, platelet count and liver stiffness, the presence of fat depletion, in all 
compartments, was significantly associated with first clinical decompensation. 
Combining the liver stiffness-spleen size-over-platelet risk score (LSPS) to the total 
adipose tissue index (TATI) lead to a new completely non-invasive index that could 
predict decompensation with an AUROC of 0.91 (Figure 2), strongly suggesting that 
both factors should be used for risk stratification in this population.  
 
When we analysed independent predictors for 12-month mortality in decompensated 
patients, MELD, sodium and IMATI were the only significant independent factors in 
multivariate analysis. A model containing MELD, sodium and IMATI could predict 12-
month mortality with an AUROC of 0.94 vs. 0.84 for MELD and 0.86 for MELD-Na, 
indicating that myosteatosis, as previously described24 has an independent 
association with mortality in decompensated cirrhosis (Figure 2). 
 
We grant there are some important limitations of our study. Although this is the 
largest study evaluating hepatic haemodynamics and all body composition 
compartments in patients with cirrhosis, it is single-centred and the population size 
remains limited with a subsequently small number of events. The small sample size 
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also limited subgroup analysis in compensated and decompensated patients. The 
retrospective study design and the indication for performing HVPG measurement 
and CT scan may introduce selection biases. The prevalence of sarcopenia was also 
considerably higher in our population than that previously reported for patients on 
transplant waiting list).20 Another limitation is the absence of functional muscle tests 
and other tests of global nutritional assessment in our patients’ evaluation. 
Additionally, as dry weight measurements were not available in patients with ascites, 
this could preclude from calculating correct BMI.  
 
In conclusion, our study shows that adipose tissue compartments, but not muscle-
related imaging markers correlate with the HVPG. In addition, reduction of 
subcutaneous adipose tissue deposits and increase in myosteatosis are significantly 
associated with the development of liver-related decompensation and death. Taking 
into consideration previous findings25,26, both skeletal muscle and fat tissue 
compartments seem to play a crucial role in the prognostic assessment of patients 
with cirrhosis. Nevertheless, given the retrospective nature and small sample size, its 
impact on prognosis must be interpreted cautiously.  Mechanistic studies addressing 
the interplay between liver, muscle and fat tissue in cirrhosis are needed. 
Furthermore, larger, prospective studies are required to evaluate the impact these 
factors play on prognosis. Although our results suggest that CT-based body 
composition assessment including subcutaneous, visceral and intramuscular fat, in 
addition to muscle5, allows  risk stratification in cirrhosis. The added benefit of such 
an approach requires further validation weighted against already substantiated 
prognostic markers.  
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Table 1. Baseline clinical, demographic, laboratory and imaging characteristics of the 
cohort by gender at HVPG/Body composition evaluation. 
 
All (N=84) Male (n= 51) Female (n= 33) P-value 
Age (years), mean±SD 57±11 59±11 55±12 0.12 
Aetiology n (%) 
Alcohol-related 
Non-alcoholic fatty liver disease (NAFLD)-related 
Hepatitis C 
Autoimmune (AI) liver disease 
Hepatitis B 
Other 
 
43 (51.2) 
20 (23.8) 
11 (13.1) 
6 (7.1) 
1 (1.2) 
3 (3.6) 
 
30 (58.8) 
11 (21.6) 
4 (7.8) 
2 (4) 
1 (2) 
3 (5.8) 
 
13 (39.4) 
9 (27.3) 
7 (21.2) 
4 (12.1) 
- 
- 
 
0.08 
0.55 
0.08 
0.15 
- 
- 
Decompensated at HVPG n (%) 46 (55) 30 (59) 16 (48) 0.24 
MELD score, mean±SD 13±8 14±9 12±7 0.20 
Child-Pugh score, mean±SD 7±2 7.5±2 7±2 0.72 
Albumin (g/L, 35-52), mean±SD 29.5±6 30±6 29±6.5 0.33 
Sodium (mmol/L, 136-145), mean±SD 138±4 139±4 138±4 0.31 
Creatinine (μmol/L, 59-104), median (IQR) 73 (60-94) 80 (68-99) 60 (51-74) 0.001 
Platelet count (G/L, 150-450), mean±SD 125±67 117±65 139±68 0.13 
Liv r stiffness (kPa), median (IQR) 35±23 37±23 31±24 0.40 
HVPG (mmHg), mean±SD 14±6.3 14.5±6.3 13.3±6.3 0.39 
Diabetes n (%) 25 (30) 16 (31) 9 (27) 0.81 
CSPH n (%) 63 (75) 40 (78) 23 (70) 0.54 
Varices n (%) 45 (54) 28 (55) 17 (52) 0.84 
Ascites n (%) 
Mild 
32 (38) 
8 
22 (43) 
4 
10 (30) 
4 
0.26 
Hepatic encephalopathy n (%) 8 (10) 5 (10) 3 (9) 0.91 
Beta-blockers n (%) 41 (49) 26 (51) 15 (46) 0.66 
Statins n (%) 15 (18) 8 (16) 7 (21) 0.57 
Diuretics n (%) 35 (42) 22 (43) 13 (39) 0.82 
Death in follow-up n (%) 16 (19) 12 (24) 4 (12) 0.26 
Episode of decompensation in follow-up n (%): 43 (51) 25 (49) 18 (55) 0.89 
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HVPG, hepatic venous pressure gradient; CSPH, clinically significant portal 
hypertension; SD, standard deviation; IQR, interquartile range 
  
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Table 2. Correlations between HVPG and body composition parameters, stratified by 
gender, sarcopenia, disease stage and aetiology 
 Correlation 
of   HVPG 
& BMI 
(P-value) 
Correlation 
of HVPG & 
SMI 
(P-value) 
Correlation 
of HVPG & 
PMI (P-
value) 
Correlation 
of HVPG & 
TATI 
(P-value) 
Correlation 
of HVPG & 
VATI 
(P-value) 
Correlation 
of HVPG & 
SATI 
(P-value)                 
Correlation 
of HVPG & 
IMATI 
(P-value) 
Correlation 
of HVPG & 
SATI/VATI 
(P-value) 
Overall -0.16 
(0.15) 
-0.006 
(0.96) 
-0.003  
(0.98) 
-0.22 
(0.045) 
-0.07  
(0.55) 
-0.28  
(0.01) 
-0.05  
(0.67) 
-0.24  
(0.03) 
Female (n=33) -0.36 
(0.04) 
-0.30  
(0.09) 
-0.29  
(0.10) 
-0.26  
(0.14) 
-0.03  
(0.89) 
-0.38  
(0.03) 
-0.03  
(0.87) 
-0.21  
(0.25) 
Male (n=51) -0.06 
(0.68) 
-0.08  
(0.6) 
0.08  
(0.60) 
-0.22  
(0.12) 
-0.15  
(0.3) 
-0.22  
(0.12) 
-0.07  
(0.63) 
-0.25  
(0.08) 
         
Sarcopenia 
(n=50) 
-0.26 
(0.07) 
- - -0.29  
(0.04) 
-0.26  
(0.07) 
-0.24  
(0.1) 
-0.15  
(0.29) 
-0.10  
(0.52) 
No 
sarcopenia 
(n=34) 
0.05 
(0.79) 
- - -0.06  
(0.74) 
0.29  
(0.09) 
-0.30  
(0.09) 
0.1  
(0.58) 
-0.47 
(0.006) 
         
Compensated 
(n=38) 
0.008 
(0.96) 
0.28  
(0.09) 
0.28  
(0.09) 
-0.068  
(0.68) 
-0.062 
(0.71) 
-0.06  
(0.73) 
-0.172 
(0.30) 
0.044 
(0.79) 
Decompens. 
(n=46) 
-0.027 
(0.86) 
-0.035 
(0.82) 
-0.04  
(0.81) 
-0.18  
(0.24) 
0.058 
(0.70) 
-0.305 
(0.04) 
0.018 
(0.91) 
-0.316 
(0.04) 
         
ALD or 
NAFLD cause 
(n=63) 
-0.16 
(0.21) 
0.041  
(0.75) 
0.045  
(0.73) 
-0.252 
(0.048) 
-0.122 
(0.34) 
-0.28  
(0.03) 
-0.098 
(0.45) 
-0.233 
(0.068) 
Other 
aetiology  
(n=21) 
-0.081 
(0.73) 
-0.137  
(0.56) 
-0.271  
(0.23) 
-0.183 
(0.43) 
-0.012 
(0.96) 
-0.287 
(0.21) 
0.048 
(0.84) 
0.055 
(0.81) 
 
 
HVPG, hepatic venous pressure gradient; BMI, body mass index; SMI, skeletal 
muscle index; PMI, psoas muscle index; TATI, total adipose tissue index; VATI, 
visceral adipose tissue index;  SATI, subcutaneous adipose tissue index;  IMATI, 
intramuscular adipose tissue index; ALD, alcoholic liver disease; NAFLD, non-
alcoholic fatty liver disease 
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Table 3. Body composition parameters according to degree of portal pressure 
(HVPG). * p=0.028 vs. <10 mmHg.  
 < 10 mm Hg 
(n=21) 
10-12 mm Hg 
(n=11) 
13-15 mm Hg 
(n=25) 
≥ 16mm Hg 
(n=28) 
BMI (kg/m
2
) 30±7 28±4 27±5 28±5 
SMI 
(cm
2
/m
2
) 
44±9 44±8 43±11 46±13 
PMI 
(cm
2
/m
2
) 
4.4±0.9 4.5±0.8 4.3±1.1 4.6±1.3 
TATI 
(cm
2
/m
2
) 
162±79 143±37 137±77 132±47 
VATI 
(cm
2
/m
2
) 
67±40 63±22 53±8 65±32 
SATI 
(cm
2
/m
2
) 
91±47 77±24 79±51 65±33* 
IMATI 
(cm
2
/m
2
)† 
3.5 (1.2-4.2) 3.0 (0.98-3.7) 2.6 (0.6-4.4) 2.6 (1.2-3.8) 
SATI/VATI† 1.4 (0.81-1.97) 1.1 (0.9-1.3) 1.5 (0.7-2.9) 0.9 (0.6-1.6) 
 
 
BMI, body mass index; SMI, skeletal muscle index; PMI, psoas muscle index; TATI, 
total adipose tissue index; VATI, visceral adipose tissue index;  SATI, subcutaneous 
adipose tissue index;  IMATI, intramuscular adipose tissue index; †expressed in 
median (IQR) 
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Table 4. Univariate Cox regression analysis of factors predicting 12-month 
decompensation in compensated patients 
Characteristics 
Compensated (n=38) 
Events (decompensation) n=7 
 
Univariate HR 
(95% CI) 
P- value 
Age 0.96 (0.90-1.03) 0.27 
Gender 0.65 (0.145-2.93) 0.58 
ALD/NAFLD vs. others 1.71 (0.38-7.8) 0.48 
Albumin 0.97 (0.83-1.21) 0.65 
Bilirubin 1.01 (0.97-1.04) 0.72 
Sodium 1.02 (0.82-1.27) 0.83 
Creatinine 0.97 (0.92-1.02) 0.20 
Platelet count 0.985 (0.97-1.001) 0.07 
Diabetes 2.62 (0.31-22.1) 0.38 
CSPH 4.78 (0.58-39.7) 0.15 
Varices 2.29 (0.44-11.9) 0.33 
HVPG 1.12 (0.99-1.26) 0.08 
Child-Pugh score 1.01 (0.56-1.8) 0.98 
MELD score 1.1 (0.85-1.41) 0.48 
MELD SATI score 1.03 (0.93-1.13) 0.60 
Liver stiffness 1.03 (0.998-1.07) 0.06 
Spleen size 1.17 (0.95-1.44) 0.15 
LSPS 1.26 (1.05-1.51) 0.013 
BMI 0.94 (0.79-1.11) 0.44 
SMI 0.97 (0.89-1.05) 0.45 
PMI 0.74 (0.33-1.69) 0.48 
TATI 0.98 (0.96-1.0003) 0.09 
VATI 0.94 (0.90-0.99) 0.01 
SATI 0.99 (0.98-1.01) 0.71 
IMATI 0.69 (0.38-1.24) 0.21 
SATI/VATI 1.75 (1.2-2.5) 0.002 
 
LSPS, liver stiffness-spleen size over platelet score; HVPG, hepatic venous pressure 
gradient; BMI, body mass index; SMI, skeletal muscle index; PMI, psoas muscle 
index; TATI, total adipose tissue index; VATI, visceral adipose tissue index; SATI, 
subcutaneous adipose tissue index;  IMATI, intramuscular adipose tissue index; 
ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease 
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Figure legends 
Figure 1. Abdominal CT images at the 3rd. lumbar vertebra of two female patients 
with cirrhosis applied for body composition assessment. Patient A had alcoholic liver 
disease, MELD 9, HVPG 16 mm Hg and low SATI (43 cm2/m2), Patient B had 
alcoholic liver disease, MELD 8, HVPG 9 mm Hg and high SATI (84 cm2/m2). 
Subcutaneous adipose tissue is shown in blue and visceral adipose tissue in yellow. 
Figure 2. (A) AUROC for liver stiffness, APRI, HVPG, LSPS and LSPS-TATI for 
predicting 12-month decompensation in compensated patients; (B) AUROC for 
MELD-sodium-IMATI to detect 12-month mortality in decompensated patients 
Supplementary Figure 1. Flowchart of patients submitted to hepatic haemodynamics 
included for the body composition analyses 
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